India's FSSAI has issued a regulatory notice to Nestle Health Science Limited over allegedly misleading advertising claims for the supplement Celevida GLP+.110 The regulator found claims linking the product to GLP-1/GIP therapies and presenting it as suitable for 'complete daily nutrition' created a misleading impression.237 This action follows recent separate regulatory cases against Nestlé India concerning infant nutrition and a dairy whitener, forming a pattern of scrutiny.1421 The company must now show cause to the regulator, and a failure to correct the claims risks penalties and further reputational harm.9
THREATRegulatory penalties, including fines and potential restrictions on product sales, for non-compliant advertising claims.9
THREATErosion of consumer trust in the Celevida GLP+ brand and the broader Nestle Health Science portfolio due to misleading claims.3517
THREATAmplification of the story as part of a narrative of repeated regulatory challenges for Nestlé in India, damaging its overall market reputation.1421
Best response strategy
REBUILD The FSSAI has made a definitive finding that specific claims are non-compliant and misleading, placing the onus on the company to correct them.3517 This is part of a pattern of recent regulatory actions against Nestlé entities in India, raising the stakes for a cooperative and corrective response.1421 The sector's duty of care for accurate health information and the regulator's clear findings necessitate a response focused on corrective action and process improvement.
Who is watching, and what each expects from the response:
regulatorEnforcement of food safety and advertising standards, and ensuring the company corrects non-compliant claims.1910
customersWhether the product's advertised health benefits are accurate and if they have been misled about its suitability for specific therapies.23511
investorsPotential financial and reputational damage from regulatory action and loss of consumer trust in the health science portfolio.91421
mediaReporting on regulatory scrutiny of a major multinational's health claims, potentially as part of a pattern of issues.1141821
Suggested response plan
T+0-4h
Phase 1 — Contain & verify
Outcome: Regulator has received our formal acknowledgement of the notice and a request for clarification, and no uncoordinated external communication has been issued.1910
legal
Immediately instruct the legal and regulatory affairs lead to formally acknowledge receipt of the FSSAI notice to Nestle Health Science Limited and request a bilateral meeting to clarify the specific non-compliant claims, while the comms lead freezes all external communication on Celevida GLP+ and prepares a holding statement.
Legal lead sends formal acknowledgement and meeting request to the designated FSSAI officer via the official channel.
Comms lead issues a directive to all market-facing teams to cease all external communication regarding Celevida GLP+ claims until further notice.
Comms lead drafts a holding statement for the website acknowledging the notice and committing to full cooperation.
Done when: FSSAI acknowledgement received and meeting requested, and zero uncoordinated comms on the product.
T+4-12h
Phase 2 — Respond to regulator and public
Outcome: A public statement committing to review the claims is live on the corporate website, and the regulator has our detailed written response outlining steps for corrective action.110
comms
Publish the public statement on the Nestle Health Science website and deliver a detailed written response to FSSAI, outlining the immediate steps to review all Celevida GLP+ marketing materials and a timeline for providing revised claims.3517
Comms lead publishes the final public statement on the Nestle Health Science corporate website 'News' section.
Legal and regulatory affairs lead finalizes and delivers the detailed written response to the FSSAI, outlining the review process and proposed corrective steps.
Done when: Statement live on the Nestle Health Science website and formal written response delivered to FSSAI.
“Nestle Health Science takes regulatory compliance with the utmost seriousness. We have received a notice from the FSSAI regarding claims made for Celevida GLP+. We are fully reviewing the matter in consultation with the regulator and are committed to ensuring all our communications are accurate and compliant. The health and trust of our consumers is our highest priority.” website statement
T+1-3 days
Phase 3 — Manage corrections and outreach
Outcome: All non-compliant claims for Celevida GLP+ have been removed from e-commerce and other platforms, and key media have been briefed on the corrective actions taken.568
operations
Direct the marketing and e-commerce operations teams to remove or revise all flagged claims for Celevida GLP+ across all platforms, and brief select health and business media on the steps taken to ensure compliance.
Marketing operations lead audits and instructs all third-party e-commerce partners to remove or replace the non-compliant claims immediately.
Comms lead conducts a background briefing with select health and business journalists, providing the timeline for corrective action without speculating on the regulator's findings.
Done when: Zero instances of the flagged claims live on any consumer-facing platform, and corrective action briefing delivered to at least three key media outlets.
T+2-5 days
Phase 4 — Recover with a counter-narrative
Outcome: Media coverage shifts to focus on the company's proactive compliance steps, and an internal review of claim-approval processes is initiated to prevent recurrence.22
comms
Commission and publish a blog post on the Nestle Health Science website detailing the company's commitment to scientific rigor and transparent labeling, and launch an internal review of the marketing claim approval process with findings to be shared with the regulator.
Comms lead authors and publishes a blog post titled 'Our Commitment to Transparency in Health Science' on the corporate site.
Legal and regulatory affairs lead formally notifies the FSSAI of the scope and timeline of the internal marketing claim review process.
Done when: Blog post live and cited in subsequent media coverage, and terms of reference for the internal review shared with the FSSAI.
Evidence sources (8)
Everything this briefing cites — ANCHOR started the story, CONTEXT backs it without naming the brand.
Your crisis desk is ready — claim it to respond. Claiming is free — your response strategy & plan become collaborative, and you get the option to display your response & status updates on this page.
One short, factual update when this story develops — nothing else, from over:heard.
Email updates
By subscribing you consent to receive email updates about this story. Double opt-in: nothing is sent until you confirm from your inbox. Unsubscribe anytime — one click in every email.
Push notifications
No email needed — alerts appear on this device.
Not nestlehealthscience.com? See what over:heard would flag for your brand.
Start free →
Independent media-monitoring briefing compiled by over:heard radar from public coverage. Assessments are decision support —
not statements by, or affiliation with, the brands mentioned. · Built from public sources, cited.
Every brand has a free, permanent right of reply —
editorial policy
· Powered by over:heard by wise:able
